

University of Pennsylvania  
Office of Regulatory Affairs  
3624 Market St., Suite 301 S  
Philadelphia, PA 19104-6006  
Ph: 215-573-2540/ Fax: 215-573-9438  
**INSTITUTIONAL REVIEW BOARD**  
(Federalwide Assurance # 00004028)

15-Jun-2015

Salimah H Meghani  
[meghanis@nursing.upenn.edu](mailto:meghanis@nursing.upenn.edu)

PRINCIPAL INVESTIGATOR	: Salimah H Meghani
TITLE	: UPCC 10909 A Novel Approach to Elucidate Mechanisms for Disparity in Cancer Pain Outcomes
SPONSORING AGENCY	: National Institute of Nursing Research/NIH/DHHS
PROTOCOL #	: 810322
REVIEW BOARD	: IRB #4

Dear Dr. Salimah Meghani:

The above referenced protocol was reviewed and re-approved using the expedited procedure set forth in 45 CFR 46.110(b) (3,5,7), on 12-Jun-2015.

**Approval by the IRB does not necessarily constitute authorization to initiate the conduct of a human subject research study. You are responsible for obtaining any relevant committee approvals.**

This approval is for the period 12-Jun-2015 to 11-Jun-2016.

**The following documents were included with this submission:**

- HS-ERA Continuing Review Request (Confirmation Code # bheaccde), submitted 05/19/2015
- IRB Self-Assessment Form, uploaded 1/28/2015
- Electronic Consent Form, uploaded 1/28/2015

When enrolling subjects at a site covered by the University of Pennsylvania's IRB, a copy of the IRB approved informed consent form with the IRB approved from/to stamp must be used unless a waiver of written documentation of consent has been granted.

If you have any questions about the information in this letter, please contact the IRB administrative staff. Contact information is available at our website: <http://www.upenn.edu/IRB/directory>.

Thank you for your cooperation.

Sincerely,

IRB Administrator